Comparison of clopidogrel vs. ticagrelor medication adherence in patients with acute coronary syndrome

Eur Rev Med Pharmacol Sci. 2023 Aug;27(15):7309-7315. doi: 10.26355/eurrev_202308_33302.

Abstract

Objective: Medication nonadherence to dual antiplatelet therapy increases major cardiovascular events. In this study, we investigated patients' post-acute coronary syndrome (ACS) medication adherence to clopidogrel and ticagrelor over a 12-month period. Furthermore, we also examined the factors that may affect medication adherence in this patient population.

Patients and methods: This study included 509 patients who were scheduled for dual antiplatelet therapy for one year following ACS (October 2018-December 2019). A proportion of days covered (PDC) method, based on a pharmacy database system, was used to determine their medication adherence. Medication adherence was defined as > 80% PDC.

Results: No difference was found between clopidogrel and ticagrelor in terms of medication adherence (68.3% vs. 64.6%, p = 0.39). Moreover, higher education levels (B = 3.24, CI: 1.17-8.9, p = 0.023) and percutaneous coronary intervention (PCI) as a revascularization option (B = 0.35, CI: 0.17-0.71, p = 0.004) predicted medication adherence independently.

Conclusions: In this research, medication adherence was found to be similar between the clopidogrel and ticagrelor groups. It was also predicted by higher education levels and revascularization with PCI.

MeSH terms

  • Acute Coronary Syndrome* / drug therapy
  • Clopidogrel / therapeutic use
  • Humans
  • Medication Adherence
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Ticagrelor / therapeutic use

Substances

  • Clopidogrel
  • Ticagrelor
  • Platelet Aggregation Inhibitors